2'-O-pentylcytidine | 160527-12-8

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 2'-O-pentylcytidine
• 英文别名: 4-amino-1-[(2R,3R,4R,5R)-4-hydroxy-5-(hydroxymethyl)-3-pentoxyoxolan-2-yl]pyrimidin-2-one
• CAS: 160527-12-8
• 化学式: C₁₄H₂₃N₃O₅
• 分子量: 313.354
• InChiKey: LOGKSBQZAQMKIU-OJAKKHQRSA-N

物化性质

• 沸点：
  527.0±60.0 °C(Predicted)
• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  118
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1-溴戊烷 、 胞苷 以 二甲基亚砜 为溶剂， 生成 2'-O-pentylcytidine
  参考文献：
  名称：

  Process for the preparation of 2'-O-alkyl purine phosphoramidites

  摘要：

  2'-O-烷基化鸟苷、尿苷、胞苷和2,6-二氨基嘌呤3'-O-磷酰胺酯是通过烷基化核苷前体、添加适当的阻断基团和磷酰化来制备的。烷基化是在2,6-二氨基-9-(β-D-核糖呋喃基)嘌呤上进行的，随后进行去氨基化以制备鸟苷2'-O-烷基化3'-O-磷酰胺酯。烷基化是在尿苷的二烷基基锡衍生物上进行的，以制备尿苷2'-O-烷基化3'-O-磷酰胺酯。烷基化是直接在胞苷上进行的，以制备胞苷2'-O-烷基化3'-O-磷酰胺酯。烷基化是直接在2,6-二氨基嘌呤上进行的，以制备2,6-二氨基嘌呤2'-O-烷基化3'-O-磷酰胺酯。

  公开号：

  US05646265A1

文献信息

• Process for the preparation of 2′-O-alkyl-guanosine, cytidine, and uridine phosphoramidites
  申请人：ISIS Pharmaceuticals, Inc.

  公开号：US06242592B1

  公开（公告）日：2001-06-05

  Processes for preparing 2′-O-alkylated guanosine, uridine, cytidine, and 2,6-diaminopurine 3′-O-phosphoramidites include the steps of alkylating nucleoside precursors, adding suitable blocking groups and phosphitylating. For the guanosine 2′-O-alkylated 3′-O-phosphoramidites, alkylation is effected on 2,6-diamino-9-(&bgr;-D-ribofuranosyl) purine followed by deamination. For uridine 2′-O-alkylated 3′-O-phosphoramidites, alkylation is effect on a dialkyl stannylene derivative of uridine. For cytidine 2′-O-alkylated 3′-O-phosphoramidites, alkylation is effected directly on cytidine. Alkylation is effected directly upon 2,6-diaminopurine.

  制备2'-O-烷基化鸟苷、尿苷、胞苷和2,6-二氨基嘌呤3'-O-磷酰胺酯的过程包括烷基化核苷前体、添加适当的阻断基和磷酰化步骤。对于鸟苷2'-O-烷基化3'-O-磷酰胺酯，烷基化作用在2,6-二氨基-9-(&bgr;-D-核糖)嘌呤上，然后进行去氨作用。对于尿苷2'-O-烷基化3'-O-磷酰胺酯，烷基化作用在尿苷的二烷基锡衍生物上。对于胞苷2'-O-烷基化3'-O-磷酰胺酯，烷基化作用直接在胞苷上。烷基化作用直接作用在2,6-二氨基嘌呤上。
• 2'-O-modified nucleosides and phosphoramidites
  申请人：ISIS Pharmaceuticals, Inc.

  公开号：US05914396A1

  公开（公告）日：1999-06-22

  2'-O-Modified nucleosides, nucleotides, and oligonucleotides. These 2'-O-modified oligonucleotides are resistant to nuclease digestion and can effectively hybridize to a complementary polynucleotide.

  2'-O-修饰核苷、核苷酸和寡核苷酸。这些2'-O修饰的寡核苷酸能够抵抗核酸酶消化，能够有效地与互补的多核苷酸杂交。
• Novel 2'-O-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof
  申请人：ISIS PHARMACEUTICALS, INC.

  公开号：EP1223173A2

  公开（公告）日：2002-07-17

  Novel 2'-O-alkyl guanosine compounds and analogs thereof are provided. Processes for the preparation of 2'-O-alkyl guanosine and analogs thereof are also provided. Processes for preparing 2'-O-alkylated guanosine, uridine, cytidine, and 2,6-diaminopurine 3'-O-phosphoramidites are also provided. Methods for the use of oligonucleotides comprising 2'-O-alkyl guanosine are also provided.

  提供了新型 2'-O- 烷基鸟苷化合物及其类似物。还提供了制备 2'-O- 烷基鸟苷及其类似物的工艺。还提供了制备 2'-O 烷基鸟苷、尿苷、胞苷和 2,6-二氨基嘌呤 3'-O 磷酰胺的工艺。还提供了使用包含 2'-O- 烷基鸟苷的寡核苷酸的方法。
• ANTISENSE OLIGONUCLEOTIDE CAPABLE OF ALTERING SPLICING OF DUX4 PRE-MRNA
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP3998108A1

  公开（公告）日：2022-05-18

  The present invention aims at establishing a novel therapy for facioscapulohumeral muscular dystrophy. An oligonucleotide or a pharmaceutically acceptable salt thereof, wherein the oligonucleotide comprises an oligonucleotide of 15-30 bases consisting of a nucleotide sequence complementary to the region of nucleotide Nos. 502-556 or 578-612 of DUX4-fl mRNA consisting of the nucleotide sequence as shown in SEQ ID NO: 1; the 5' and/or 3' end of the oligonucleotide may be chemically modified; and the oligonucleotide is capable of switching the splice form of the DUX4 gene from DUX4-fl to DUX4-s. A pharmaceutical drug comprising the above oligonucleotide or a pharmaceutically acceptable salt thereof (e.g. therapeutic for facioscapulohumeral muscular dystrophy).

  本发明的目的是建立一种治疗面肱骨肌营养不良症的新型疗法。 一种寡核苷酸或其药学上可接受的盐，其中寡核苷酸包括由与 DUX4-fl mRNA 的核苷酸 Nos.寡核苷酸的 5'端和/或 3'端可进行化学修饰；并且寡核苷酸能够将 DUX4 基因的剪接形式从 DUX4-fl 转换为 DUX4-s。一种包含上述寡核苷酸或其药学上可接受的盐的药物（如治疗面肱骨肌营养不良症）。
• GALNAC-OLIGONUCLEOTIDE CONJUGATE FOR LIVER-TARGETED DELIVERY USE, AND METHOD FOR PRODUCING SAME
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP4029520A1

  公开（公告）日：2022-07-20

  The present invention provides a conjugate of an oligonucleotide having a nucleic acid sequence expected to have a pharmacological effect in hepatic parenchymal cells with a biantennary GalNAc unit, or a pharmaceutically acceptable salt thereof, and a medicament or the like containing the same as an active component.

  本发明提供了一种寡核苷酸的共轭物，该寡核苷酸具有可望在肝实质细胞中产生药理作用的核酸序列，带有一个双年基 GalNAc 单元，或其药学上可接受的盐，以及一种含有相同的寡核苷酸作为活性成分的药物或类似物。